The cell-penetrating peptide IMT-P8 produced stronger antibody and T cell responses than LDP12 when used to deliver an HIV vaccine antigen in mice.
IMT-P8 superior across all measuresIMT-P8 produced significantly higher antibodies, IFN-gamma, and cytotoxic T cell activation than LDP12 for HIV antigen delivery
What the researchers found
IMT-P8 linked to the HIV Nef-MPER-V3 antigen produced significantly higher IgG antibody levels than LDP12-linked antigen. When combined with HP91 adjuvant, IMT-P8 generated the strongest humoral response. IMT-P8 also induced more robust IFN-gamma production and cytotoxic T cell activation compared to LDP12, indicating superiority as both a humoral and cellular immune activator.
Why it matters
Cell-penetrating peptides are a promising technology for delivering vaccine antigens directly into immune cells, potentially improving vaccine efficacy. Identifying which CPPs work best for immune stimulation helps advance peptide-based vaccine delivery platforms — relevant beyond just HIV vaccines.
The numbers in context
Two CPPs (IMT-P8 and LDP12) and two adjuvants (HP91 and HSP27) tested in female BALB/c mice.
How the study worked
Animal study in female BALB/c mice. Recombinant fusion proteins were generated linking the HIV Nef-MPER-V3 antigen to either IMT-P8 or LDP12 cell-penetrating peptides. Mice were immunized with different regimens using HP91 or HSP27 as adjuvants. Immune responses were measured via ELISA for antibodies, cytokines, and granzyme B, plus CTL proliferation assays.
Who was studied
Female BALB/c mice in vaccination study
What this study cannot tell us
Mouse study only — immune responses in BALB/c mice may not predict human responses. Only female mice were used. No challenge study was performed, so it's unknown whether the immune responses would actually protect against HIV infection. Small-scale preclinical work.
How to read the evidence
Rated preliminary: small-scale mouse vaccination study without viral challenge. Promising for CPP development but far from clinical application.
When this study was published
Published in 2024. Contributes to ongoing research comparing cell-penetrating peptides for vaccine delivery applications.
The bigger picture
Cell-penetrating peptides represent a growing toolkit for delivering biological cargo into cells. This head-to-head comparison helps refine which CPPs are best suited for vaccine applications, with broader implications for peptide-based drug delivery.
Questions still open
- Would IMT-P8 superiority over LDP12 hold in human immune cells?
- Could IMT-P8 improve delivery for vaccines against other pathogens beyond HIV?
- Does the stronger immune response from IMT-P8 translate to actual protection against viral challenge?
Common questions
What are cell-penetrating peptides?
Could peptides improve HIV vaccines?
Read the original research
Comparative Analysis of IMT-P8 and LDP12 Cell-Penetrating Peptides in Increasing Immunostimulatory Properties of HIV-1 Nef-MPER-V3 Antigen.
Protein and peptide letters, 31(10), 818-826
Citation
Sadat, Seyed Mehdi; Jahedian, Shekoufa; Sabaghzadeh, Sahar; Larijani, Mona Sadat; Bolhassani, Azam. (2024). Comparative Analysis of IMT-P8 and LDP12 Cell-Penetrating Peptides in Increasing Immunostimulatory Properties of HIV-1 Nef-MPER-V3 Antigen.. Protein and peptide letters, 31(10), 818-826. https://doi.org/10.2174/0109298665337811241010104557